Portugal's Self-Medication Market

12 November 1997

Portugal is Europe's fastest-growing self-medication market, advancingnearly 18% a year, says a new study from James Dudley Management.

1997 sales of non-prescription-bound products are put at $194 million. Growth since 1992 has totaled 351% and has been particularly strong since 1995, when a large number of prescription drugs began to be switched to over-the-counter status. Driven by continuing switches, the market is expected to grow 220% by 2005, rising especially fast in 1998-2003 and then slowing down to 5%-6% growth to 2005.

The largest OTC categories at present are gastrointestinal and upper respiratory tract products, with 19% of the market each. The fastest-growing category is vitamins/minerals/supplements, with sales in 1997 forecast to be 10 times higher than in 1992. Highest growth in the reporting period will be pain relief, growing 272% to 2005 due to product switches.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight